1. Home
  2. ACRS vs CIGL Comparison

ACRS vs CIGL Comparison

Compare ACRS & CIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ACRS
  • CIGL
  • Stock Information
  • Founded
  • ACRS 2012
  • CIGL 1997
  • Country
  • ACRS United States
  • CIGL Singapore
  • Employees
  • ACRS N/A
  • CIGL N/A
  • Industry
  • ACRS Biotechnology: Pharmaceutical Preparations
  • CIGL Diversified Commercial Services
  • Sector
  • ACRS Health Care
  • CIGL Consumer Discretionary
  • Exchange
  • ACRS Nasdaq
  • CIGL Nasdaq
  • Market Cap
  • ACRS 165.7M
  • CIGL 145.9M
  • IPO Year
  • ACRS 2015
  • CIGL 2025
  • Fundamental
  • Price
  • ACRS $1.59
  • CIGL $4.21
  • Analyst Decision
  • ACRS Strong Buy
  • CIGL
  • Analyst Count
  • ACRS 9
  • CIGL 0
  • Target Price
  • ACRS $9.25
  • CIGL N/A
  • AVG Volume (30 Days)
  • ACRS 1.3M
  • CIGL 669.5K
  • Earning Date
  • ACRS 08-06-2025
  • CIGL 01-01-0001
  • Dividend Yield
  • ACRS N/A
  • CIGL N/A
  • EPS Growth
  • ACRS N/A
  • CIGL N/A
  • EPS
  • ACRS N/A
  • CIGL N/A
  • Revenue
  • ACRS $17,777,000.00
  • CIGL $10,490,668.00
  • Revenue This Year
  • ACRS N/A
  • CIGL N/A
  • Revenue Next Year
  • ACRS $11.77
  • CIGL N/A
  • P/E Ratio
  • ACRS N/A
  • CIGL N/A
  • Revenue Growth
  • ACRS N/A
  • CIGL N/A
  • 52 Week Low
  • ACRS $1.05
  • CIGL $2.12
  • 52 Week High
  • ACRS $5.17
  • CIGL $31.06
  • Technical
  • Relative Strength Index (RSI)
  • ACRS 59.88
  • CIGL N/A
  • Support Level
  • ACRS $1.44
  • CIGL N/A
  • Resistance Level
  • ACRS $1.52
  • CIGL N/A
  • Average True Range (ATR)
  • ACRS 0.10
  • CIGL 0.00
  • MACD
  • ACRS 0.00
  • CIGL 0.00
  • Stochastic Oscillator
  • ACRS 79.17
  • CIGL 0.00

About ACRS Aclaris Therapeutics Inc.

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.

About CIGL Concorde International Group Ltd Class A Ordinary Shares

Concorde International Group Ltd is an integrated security services provider that combines physical manpower and technology to deliver effective security solutions. The company offers a range of services to enhance security and safety: (1) i-Guarding Services; (2) Man-Guarding Services; and (3) Consultancy and Training Services. Its i-Guarding Services leverages technology to increase efficiency, with a mobile platform and cluster aggregation model of a higher skillset workforce. It has two operating segments, which are (i) security services; and (ii) training school. Key revenue is generated from Security Services.

Share on Social Networks: